Drugs / Omega-3 Fatty Acid Supplement
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04495816 Comparator | Jul 2020 → Dec 2021 | COVID-19, anosmia | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Omega-3 Fatty Acid Supplement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04495816 ↗ |
| Known as | Fish Oil, Ultra Omega-3 | “The intervention group will receive 2000 mg daily of omega-3 supplementation in the form of two "Fish Oil, Ultra Omega-3" capsules (product of Pharmavite®) daily.” PMID 33225989 ↗ Nov 2020 |
| Route | Oral | “Participants randomized to this arm will be instructed to take two of the softgels they received per day for 6 weeks.” NCT04495816 ↗ |